A Phase 3 study evaluating CagriSema (Cagrilintide B and Semaglutide I) for Type 2 Diabetes Mellitus reached primary completion on 2026-06-02. This trial, which enrolled 1023 participants, is comparing CagriSema to tirzepatide in individuals treated with metformin, SGLT2 inhibitor, or both.
Background
CagriSema is an investigational medicine being studied for the treatment of Type 2 Diabetes Mellitus. This particular study compares its effects on blood sugar and body weight against tirzepatide, a medicine currently available in some countries for this condition.
Trial design
The Phase 3 study (NCT06534411) has an enrollment of 1023 participants with Type 2 Diabetes Mellitus. The trial is designed to assess how much CagriSema lowers blood sugar and body weight compared to tirzepatide. Participants are randomly assigned to receive either CagriSema or tirzepatide, with the study duration for each participant lasting up to 1 year and 4 months. The study includes interventions with cagrilintide, semaglutide, and tirzepatide.
What this means
The primary completion of this Phase 3 study for CagriSema indicates that data collection for the main objectives has concluded. While this marks a significant milestone in the development of CagriSema for Type 2 Diabetes Mellitus, specific results regarding its efficacy in lowering blood sugar and body weight compared to tirzepatide are not yet available. Clinicians and researchers will await the full analysis and publication of these results to understand the potential role of CagriSema in managing Type 2 Diabetes.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06534411, titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both", was posted on 2026-06-02 on clinicaltrials.gov.